The Company accounts for employee and non-employee stock options under ASC 718, whereby option costs are recorded based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Unless otherwise provided for, the Company covers option exercises by issuing new shares.

The Company’s stock option activity is described below.

 
Non-employee stock options

At the beginning of 2012, the Company had 22,500 options outstanding for shares in TransBiotec – CA. During the year ended December 31, 2012 no options were exercised or expired, leaving a December 31, 2012 outstanding balance of 22,500 non-employee stock options, exercisable at prices from $0.10 - $0.15 per share with the option terms expiring from January 2012 through January 2015. All of these options are for the stock of TransBiotec - CA. During the year ended December 31, 2013 no options were exercised or expired, leaving a December 31, 2013 outstanding balance of 22,500 non-employee stock options, exercisable at $0.10 per share with the option terms expiring in January 2015. During the six months ended June 30, 2014, 20,000 options were exercised, leaving a June 30, 2014 outstanding balance of 2,500 non-employee stock options, exercisable at $0.10 per share with the option terms expiring in January 2015.All outstanding options are for the stock of TransBiotec-CA

During 2012 the Company granted 29,678 stock options for shares in TransBiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 0.8%, dividend yield of 0%, expected life of five years, volatility of 189%. No options were exercised or expired, leaving a December 31, 2012 outstanding balance of 29,678 options for TransBiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $4,042 in 2012.

During 2013 the Company granted 5,321,735 stock options for shares in TransBiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rates between 7% - 14%, dividend yield of 0%, expected life of five years, volatility between 179% - 186%. No options were exercised or expired, leaving a December 31, 2013 outstanding balance of 5,351,413 options for TransBiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $145,997 in 2013.

During the six months ended June 30, 2014 the Company granted 3,232,848 stock options for shares in TransBiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate between 1.52% - 1.70%, dividend yield of 0%, expected life of five years, a volatility range of 180% - 185%. No options were exercised or expired, leaving a June 30, 2014 outstanding balance of 8,524,261 options for TransBiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $39,355 during the six months ended June 30, 2014.

A summary of stock option activity for California is as follows:
 

Following is a summary of the status of options for California outstanding at June 30, 2014:
 

A summary of stock option activity for Delaware is as follows:
 

 
 Following is a summary of the status of options for Delaware outstanding at June 30, 2014:
 

Employee stock options

The parent company had no outstanding employee stock options.

Stock subscriptions payable

At June 30, 2014 and December 31, 2013, the Company had stock subscriptions payable of $28,067 for 26,000 common shares to be issued.